Current Studies on the Effect of Antimetabolites in Nephrosis, Other Non-Neoplastic Diseases, and Experimental Animals
Authors: HOWARD C. GOODMAN
Journal: Annals of Internal Medicine (1963)

Clinical Staff Conference1 September 1963Current Studies on the Effect of Antimetabolites in Nephrosis, Other Non-Neoplastic Diseases, and Experimental AnimalsCombined Clinical Staff Conference at the National Institutes of HealthHOWARD C. GOODMAN, M.D., SHELDON M. WOLFF, M.D., ROBERT R. CARPENTER, M.D., BURTON R. ANDERSEN, M.D., MICHAEL W. BRANDRISS, M.D.HOWARD C. GOODMAN, M.D.Search for more papers by this author, SHELDON M. WOLFF, M.D.Search for more papers by this author, ROBERT R. CARPENTER, M.D.Search for more papers by this author, BURTON R. ANDERSEN, M.D.Search for more papers by this author, MICHAEL W. BRANDRISS, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-59-3-388 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDr. Howard C. Goodman: During the past 2 years, drugs which were developed for the chemotherapy of cancer and which function as antimetabolites have been administered to patients with non-neoplastic diseases. Enough remarkable remissions of these non-neoplastic diseases have occurred to indicate an interesting new development in medicine. The purpose of this conference is to review this development briefly and to present work which, although in progress, can already document both the clinical effectiveness and the toxicity of one of the purine antimetabolites, 6-thioguanine. We will also describe some experimental approaches designed to study the mechanism of action of the...References1. BALDWINMCLEANCHASISGOLDRING DSPGHW: Effect of nitrogen mustard on clinical course of glomerulonephritis. Arch. Intern. Med. 92: 162, 1953. CrossrefGoogle Scholar2. DUBOIS EL: Nitrogen mustard in treatment of systemic lupus erythematosus. Arch. Intern. Med. 93: 667, 1954. CrossrefGoogle Scholar3. SCHWARTZSTACKDAMESHEK RJW: Effect of 6-mercaptopurine on antibody production. Proc. Soc. Exp. Biol. Med. 99: 164, 1958. CrossrefMedlineGoogle Scholar4. STERZLHOLUB JM: The influence of 6-mercaptopurine on antibody formation. Folia Biol. (Praha) 4: 59, 1958. Google Scholar5. LA PLANTECONDIEGOOD ESRMRA: Prevention of secondary immune response with 6-mercaptopurine. J. Lab. Clin. Med. 59: 542, 1962. MedlineGoogle Scholar6. HOYERHOYERGOODCONDIE JRLWRARM: The effect of 6-mercaptopurine on delayed hypersensitivity in guinea pigs. J. Exp. Med. 116: 679, 1962. CrossrefMedlineGoogle Scholar7. MEEKERCONDIEWANERVARCOGOOD WRDRRA: Prolongation of skin homograft survival in rabbits by 6-mercaptopurine. Proc. Soc. Exp. Biol. Med. 102: 459, 1959. CrossrefGoogle Scholar8. HOVERGOODCONDIE LWRARM: Experimental allergic encephalomyelitis: the effect of 6-mercaptopuiine. J. Exp. Med. 116: 311, 1962. CrossrefMedlineGoogle Scholar9. FRIEDMANBUCKLERBARON RMCES: The effect of amino-methylpteroylglutamic acid on the development of skin hypersensitivity and on antibody formation in guinea pigs. J. Exp. Med. 114: 173, 1961. CrossrefMedlineGoogle Scholar10. UPHOFF DE: Drug induced immunological "tolerance" for homo-transplantation. Transplant. Bull. 28: 110, 1961. CrossrefGoogle Scholar11. DAMESHEKSCHWARTZ WR: Treatment of certain "auto-immune" diseases with antimetabolites: preliminary report. Trans. Ass. Amer. Physicians 73: 113, 1960. MedlineGoogle Scholar12. SCHWARZANDRÉ RJ: The chemical suppression of immunity, in Mechanism of Cell and Tissue Damage Produced by Immune Reactions, edited by P. Grabar, and P. Miescher, B. Schwabe and Co., Basel, 1962, p. 385. CrossrefGoogle Scholar13. LEEMEISELASZINGALERICHMAN SLLESBSM: Effect of 6-mercaptopurine administration on antibody production and clinical course in systemic lupus erythematosus: report of a case. Arthritis Rheum. 4: 56, 1961. CrossrefMedlineGoogle Scholar14. EISENDEMISCROSBY BDJWH: Thioguanine therapy: systemic lupus erythematosus, atopic dermatitis and other non-malignant diseases. JAMA 179: 789, 1962. MedlineGoogle Scholar15. PAGECONDIEGOOD ARRMRA: Clinical studies on the anti-inflammatory activity of 6-mercaptopurine (abstract). Blood 20: 118, 1962. Google Scholar16. MACKAYWOOD IRIJ: The course and treatment of lupoid hepatitis. Gastroenterology 45: 4, 1963. CrossrefMedlineGoogle Scholar17. VAN SCOTT EJ: Biological changes with antimetabolites (abstract). Proc. 12th Int. Congr. Derm., Excerpta Med. (XIII) 52: 9, 1962. Google Scholar18. O'BRIENVAN SCOTTBLACKEISENBUNIM WMEJRLAZJJ: Clinical trial of amethopterin in psoriatic and rheumatoid arthritis (preliminary report). Arthritis Rheum. 5: 312, 1962. Google Scholar19. WEISSDEMISELGARTBROWNCROSBY HJJDMLCSWH: Treatment of two cases of hyperglobulinemic purpura. New Eng. J. Med. 268: 753, 1963. CrossrefMedlineGoogle Scholar20. GOODMANBAXTER HCJL: The nephrotic syndrome: clinical observations on therapy with prednisone and other steroids. JAMA 165: 1798, 1957. CrossrefMedlineGoogle Scholar21. ELIONHITCHINGS GBGH: The synthesis of 6-thioguanine. J. Amer. Chem. Soc. 77: 1676, 1955. CrossrefGoogle Scholar22. ELIONCALLAHANHITCHINGSRUNDLESLAXLO GBSWGHRWJ: Experimental clinical and metabolic studies of thiopurines. Cancer Chemother. Rep. 16: 197, 1962. MedlineGoogle Scholar23. LE PAGEJONES GAM: Further studies on the mechanism of action of 6-thioguanine. Cancer Res. 21: 1590, 1961. MedlineGoogle Scholar24. PHILIPSSTERNBERGHAMILTONCLARKE FSSSLDA: The toxic effects of 6-mercaptopurine and related compounds. Ann. NY Acad. Sci. 60: 283, 1954. CrossrefMedlineGoogle Scholar25. DUSTANCORCORANHASERICK HPACJP: Urinary sediment in acute diffuse lupus erythematosus. Nature and response to treatment, read before the National Meeting of American Federation for Clinical Research, Atlantic City, N. J., May, 1951. Not published. Google Scholar26. GUBNERAUGUSTGINSBERG RSV: Therapeutic suppression of tissue reactivity; II. Effect of aminopterin in rheumatoid arthritis and psoriasis. Amer. J. Med. Sci. 221: 176, 1951. CrossrefMedlineGoogle Scholar27. SCHWARTZDAMESHEK RW: The treatment of auto-immune hemolytic anemia with 6-mercaptopurine and thioguanine. Blood 19: 483, 1962. CrossrefMedlineGoogle Scholar28. MERRILL JP: Treatment of renal disease with combined steroid therapy and anti-metabolites (abstract). Blood 20: 119, 1962. Google Scholar29. BEARNKUNKELSLATER AGHGRJ: The problem of chronic liver disease in young women. Amer. J. Med. 21: 3, 1956. CrossrefMedlineGoogle Scholar30. WOLFFGOODMAN SMHC: Effect of purine antimetabolites on serum globulins in the rabbit. Proc. Soc. Exp. Biol. Med. 112: 416, 1963. CrossrefMedlineGoogle Scholar31. REBUCKBOYDRIDDLE JWCBJN: Skin windows and the action of the reticuloendothelial system in man. Ann. NY Acad. Sci. 88: 30, 1960. CrossrefMedlineGoogle Scholar32. LOVELLGOODMANHUDSONARMITAGEPICKERING RRHCBPCW: The effects of cortisone and adrenocorticotrophic hormone on experimental inflammations in the human skin. Clin. Sci. 12: 41, 1953. MedlineGoogle Scholar33. BRANDRISS MW: Methotrexate; suppression of experimental allergic encephalomyelitis. Science 140: 186, 1963. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Bethesda, MarylandThis is an edited transcription of a combined clinical staff conference at the Clinical Center, Bethesda, Maryland, by the National Institute of Allergy and Infectious Diseases, National Institutes of Health, Public Health Service, Department of Health, Education, and Welfare.Requests for reprints should be addressed to Howard C. Goodman, M.D., National Institute of Allergy and Infectious Diseases, Bethesda 14, Maryland. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited ByANTIMALARIALS AND IMMUNOSUPPRESSIVE THERAPIESDie cutan-allergische Reaktion auf 2,4-Dinitrochlorbenzol bei kindlichen Leuk�mien und soliden TumorenImmunosuppressive TherapyCytotoxic Drugs in Treatment of Nonmalignant DiseasesALFRED D. STEINBERG, M.D., PAUL H. PLOTZ, M.D., SHELDON M. WOLFF, M.D., F.A.C.P., VERNON G. WONG, M.D., SAUL G. AGUS, M.D., JOHN L. DECKER, M.D., F.A.C.P.Antimetabolite therapy in the post-myocardial-infarction syndromeImmunosuppressive therapy in polymyositisAn Introduction to ImmunosuppressantsEFFECT OF 6–MERCAPTOPURINE ON AMINONUCLEOSIDE–INDUCED PROTEINURIA IN RATSDeterioration of Renal Function after Discontinuation of Long-Term Prednisone-Azathioprine Therapy in Primary Renal DiseaseManagement of the nephrotic syndrome.Treatment of Advanced Wegener's Granulomatosis with Azathioprine and Duazomycin aKlinik und Therapie der GlomerulonephritidenSuccessful therapy of trimethadione nephrosis with prednisone and cyclophosphamideImmunosuppressive Therapy of Chronic Renal DiseaseZur Therapie glomerulärer Nierenerkrankungen mit CytostatikaChemical Suppression of Adaptive ImmunityChronic Active Hepatitis Treated with 6-Mercaptopurine—Sustained RemissionJOSEPH E. GEENEN, M.D., GEORGE T. HENSLEY, M.D., DANIEL H. WINSHIP, M.D.AnnotationsAzathioprine therapy of ?autoimmune? diseasesTreatment of Steroid-resistant Nephrotic SyndromeThe course of systemic lupus erythematosusThe management of childhood nephrosisMercaptopurine in the Treatment of Steroid-Resistant Nephrotic SyndromeThe Treatment of NephrosisStudies on adjuvant-induced polyarthritis in rats. III. The effect of “immunosuppressive agents” on arthritis and tuberculin hypersensitivityImmunosuppression and InfectionThe Effect of 6-Mercaptopurine on Immune Response in Man 1 September 1963Volume 59, Issue 3Page: 388-407KeywordsCancer chemotherapyChemotherapyChronic hepatitisDrugsEncephalomyelitisInfectious diseasesMedical servicesPrevention, policy, and public healthPurinesToxicity Issue Published: 1 September 1963 PDF DownloadLoading ...